Conditions · Alzheimer's disease & early-stage dementia
Alzheimer's disease & early-stage dementia — frontier options in California
Prefer to look first? Browse the live map without signing up.
30 open options
- TRIALPHASE3RECRUITING
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
KarXT — 429 sites
- TRIALPHASE3RECRUITING
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Acoramidis · Placebo oral tablet — 104 sites
- TRIALPHASE2RECRUITING
A Study of Donanemab (LY3002813) in Participants With Early Cognitive Decline (TRAILBLAZER-ALZ 7)
Donanemab · Placebo — 72 sites
- TRIALNARECRUITING
BID WM Digital Intervention in Aging
Coherence · Worder — 1 site
- TRIALPHASE2RECRUITING
Caring Recharge Project for Caregivers of Individuals With Alzheimer's Disease
Recharge Behavioral Therapy · Traditional Educational/Resources Program — 1 site
- TRIALNAENROLLING_BY_INVITATION
AI-Supported Cognitive Rehabilitation for Older Adults With Mild Cognitive Impairment
AI-Supported Cognitive Rehabilitation — 1 site
- TRIALPHASE2ENROLLING_BY_INVITATION
An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis
ML-007C-MA — 8 sites
- TRIALPHASE2RECRUITING
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
ML-007C-MA · Placebo — 55 sites
- TRIALNANOT_YET_RECRUITING
Ultrasonic Debris Clearance to Promote Brain Resilience
Ultrasonic Debris Clearance · sham — 1 site
- TRIALPHASE1RECRUITING
A Study to Evaluate the Drug Levels, Absolute Bioavailability, Safety, Tolerability, and Immunogenicity of Single-Dose of BMS-986446 in Healthy Adults After Single-dose Administration, and Participants With Early Alzheimer's Disease After Multiple Dose Administration
BMS-986446 — 6 sites
- TRIALNAENROLLING_BY_INVITATION
Assessing and Improving the Durability of Compensatory Cognitive Training for Older Veterans
Motivationally-Enhanced Compensatory Cognitive Training (ME-CCT) Booster Modules · Treatment As Usual — 1 site
- TRIALNARECRUITING
The Active Mind Trial: An Adaptive Randomized Trial to Improve Function and Delay Dementia
Cognitive Training · Computerized Cognitive Stimulation — 6 sites
- TRIALPHASE2RECRUITING
A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease
VHB937 · VHB937 · Placebo — 74 sites
- TRIALPHASE1 / PHASE2NOT_YET_RECRUITING
A Nutritional and Pharmacological Intervention for Body, Brain, and Longevity Effects (NIBBLE)
FMD1 (LNT22-017-1) · Rapamycin · Placebo — 1 site
- TRIALNARECRUITING
Remotely-supervised Neuromodulation in PPA
Lexical Retrieval Cascade Treatment · Remotely Supervised Transcranial Direct Current Stimulation- Active · Remotely Supervised Transcranial Direct Current Stimulation - Sham — 2 sites
- TRIALPHASE3RECRUITING
A Study of Donanemab (LY3002813) in Participants Who Completed Study AACM (TRAILBLAZER-ALZ 3-EXT).
Donanemab · Placebo — 59 sites
- TRIALPHASE3ENROLLING_BY_INVITATION
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
ACP-204 — 76 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
KarXT · KarX-EC · Placebo — 119 sites
- TRIALPHASE2RECRUITING
A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004)
MK-2214 · Placebo — 80 sites
- TRIALPHASE1NOT_YET_RECRUITING
A Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
LY4560736 · LY4560736 · Placebo — 16 sites
- TRIALNANOT_YET_RECRUITING
SleepSMART for Veterans With Insomnia and Mild Cognitive Impairment
Cognitive BehavioralTherapy for Insomnia (CBT-I) · SleepSMART — 1 site
- TRIALPHASE3RECRUITING
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
KarXT · Placebo — 296 sites
- TRIALPHASE1RECRUITING
A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD)
LY4006895 · Placebo — 13 sites
- TRIALPHASE1 / PHASE2RECRUITING
First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia
[18F]RP-115 PET/MRI or PET/CT and MRI — 1 site
- TRIALNARECRUITING
Transcranial Photobiomodulation (tPBM) in Alzheimer's Disease Study
Photobiomodulation — 1 site
- TRIALPHASE2 / PHASE3RECRUITING
A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug · Matching Placebo (Remternetug) — 37 sites
- TRIALPHASE3RECRUITING
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
KarXT · KarX-EC · KarXT + KarX-EC Arm Matching Placebo — 22 sites
- TRIALPHASE3RECRUITING
Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
No Intervention — 229 sites
- TRIALPHASE2 / PHASE3RECRUITING
A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation
Remternetug (SC) · Matching Placebo (Remternetug) — 37 sites
- TRIALPHASE1RECRUITING
CogT pSOPT Intervention Study
pSOPT · MLA — 1 site
Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗
Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.